Skip to main content
. 2021 Feb 2;11:616075. doi: 10.3389/fneur.2020.616075

Table 3.

Cardiac findings.

Patient Muscle enzymes Cardiac testing Kidney function Respiratory function
Creatine kinase (U/L)a Aldolase (U/L)b Troponin-T (ng/ml)c NTproBNP (pg/ml)d QT interval duration (ms)e Ejection fraction (%) Increased wall thickness (Y/N) Restrictive vs. dilated CMP CQ/HCQ CMP Creatinine (mg/dl)f Vital capacity (%)g
1 110 6.8 447 66 N No 1.1 89
2 557
3 244 5.1 0.12 2,896 457 72 Y R Most likely 1.2 89
4 651 8.5 <0.01 468 70 N No 0.9 123
5 125 6.4 448 65 N No 0.8 82
6 1,199 35.7 0.76 8,812 498 32 N D No 1 33
7 149 4.1 447 50 N R Possible 0.5 47
8 403 493 70 Y R Most likely 0.9 68
9 560 0.09 4,786 432 49 N R No 0.8 58
10 337 6.4 1.1 79
11 386 0.17 4,277 560 69 Y R Most likely 0.9
12 135 6.9 0.13 7,255 476 27 N R Possible 2.8 61
13 302 0.36 25,681 634 33 Y R Definite 1.1

Abnormal values are in bold.

Normal range:

a

38–176 U/L, except patients #2 and #5: 52–336 U/L;

b

<7.7 U/L;

c

<0.01 ng/ml;

d

≤ 206 pg/ml;

e

400–440 ms.

f

Females: 0.59–1.04 mg/dl and males 0.74–1.35 mg/dl.

g

≥70% of predicted.

CQ, chloroquine; HCQ, hydroxychloroquine; CMP, cardiomyopathy; D, dilated cardiomyopathy; NTproBNP, N-terminal pro-brain natriuretic peptide; R, restrictive cardiomyopathy.